IMCD (IMCD) Investor presentation summary

Business overview and strategy

• Leading global distributor and formulator of specialty chemicals and ingredients, operating in over 60 countries with 5,246 professionals and 86 technical labs.

• Asset-light business model with high cash conversion, focusing on value-added services and technical expertise.

• Eight business groups target strategic market segments, including pharmaceuticals, food & nutrition, coatings, and advanced materials.

• Growth driven by a balance of organic expansion and over 100 targeted acquisitions, supported by a unique global IT system.

• High barriers to entry, exclusive supplier relationships, and a diversified portfolio underpin resilience and profitability.

Financial performance (HY 2026)

• Revenue reached €2,638 million, up 7% year-on-year; gross profit rose 4% to €658 million.

• Operating EBITA increased 4% to €285 million, with a margin of 10.8%; net result grew 10% to €142 million.

• Free cash flow surged 29% to €222 million, with a cash conversion margin of 76.2%.

• Net debt stood at €1,560 million, with a leverage ratio of 2.8x and investment grade ratings from Moody’s and Fitch.

• Segment performance: EMEA and Asia-Pacific showed organic and acquisition-driven growth, while Americas faced a slight organic decline.

Operational excellence and digitalisation

• Fully integrated global IT system accelerates innovation, commercial, marketing, and operational processes.

• Digital tools like MyIMCD and SalesAssistant enhance omnichannel customer experience and sales team productivity.

• Supply chain is agile, resilient, and digitally connected, ensuring regulatory compliance and decarbonisation.